TachoSil

Drug Overview

In the clinical field of hematology and surgical care, achieving rapid control of blood loss is a critical priority for patient safety. TachoSil is a specialized medical product classified as a Topical Hemostatic and Fibrin Sealant. It is a highly advanced BIOLOGIC that combines a flexible collagen sponge with active human clotting proteins to seal wounds and stop bleeding directly at the surgical site.

Unlike traditional liquid sealants that require mixing and preparation, TachoSil comes as a ready-to-use medicated sponge. It is specifically designed for situations where standard surgical techniques, such as sutures (stitches) or staples, are not enough to control bleeding.

• Generic Name: Fibrinogen / Thrombin (Human) on a Collagen Sponge
• US Brand Names: TachoSil
• Route of Administration: Topical (Applied directly to the tissue surface)
• FDA Approval Status: FDA-approved as an adjunct to hemostasis in adults undergoing cardiovascular and hepatic (liver) surgery.

What Is It and How Does It Work? (Mechanism of Action)

TachoSil acts as a BIOLOGIC that bypasses the early, time-consuming steps of this cascade. The sponge is coated with two dry, human-derived proteins: Fibrinogen and Thrombin. When the sponge comes into contact with blood or other body fluids at the surgical site, these proteins dissolve and activate immediately.

1. Chemical Reaction: The thrombin acts as an enzyme that converts the fibrinogen into fibrin threads.
2. Mechanical Seal: These fibrin threads weave together, bonding the collagen sponge firmly to the surface of the organ or tissue.
3. Hemorrhage Risk Reduction: This creates a liquid-tight and air-tight seal within 3 to 5 minutes.

By providing these clotting factors directly to the wound, TachoSil ensures that a stable fibrin clot forms even if the patient has a weakened natural clotting system. The collagen sponge also provides a physical scaffold that supports the clot as the body begins the natural healing process.

FDA-Approved Clinical Indications

Primary Indication

In the drug category of hematology and surgical support, TachoSil is primarily used for the control of bleeding (hemostasis) during surgery. It is indicated for use in adults as an add-on therapy when standard surgical techniques are insufficient. Its most common applications are in:

• Cardiovascular Surgery: Used to seal blood vessel grafts or heart tissue where fine needles might leave small holes that leak blood.
• Hepatic (Liver) Surgery: Used to control oozing from the large, blood-rich surface of the liver after a portion has been removed.

Other Approved & Off-Label Uses

While its primary focus is liver and heart surgery, it is often utilized by specialists in other complex scenarios:

• Kidney Surgery: Used to control bleeding after a tumor is removed from the kidney (Partial Nephrectomy).
• Lung Surgery: Used off-label to seal air leaks in the lungs (Aerostasis) after tissue removal.
• Spleen and Pancreas Procedures: Applied to delicate tissues in the lymphatic and digestive systems that are difficult to stitch.
• Bone Marrow Procedures: Occasionally used in extreme cases to control bleeding at a bone biopsy site in patients with severe bleeding disorders.

Dosage and Administration Protocols

TachoSil is applied topically during an operation. The “dose” is determined by the surface area of the wound that needs to be covered. Surgeons select the number and size of patches based on the extent of the bleeding.

Important Adjustments:

• Application Technique: The sponge must be applied to a relatively dry surface. Surgeons often “blot” the area before application.
• Pressure: Once applied, the patch must be held in place with steady, gentle pressure using a moistened glove or pad for at least 3 minutes.
• Maximum Dose: While there is no weight-based limit, the total number of patches used should be the minimum required to achieve hemostasis.
• Infusion Rates: Not applicable, as this medication is never injected or infused into the bloodstream.

Clinical Efficacy and Research Results

Clinical studies from 2020 through 2026 continue to highlight TachoSil as a superior option for hemorrhage risk reduction in the operating room. In a series of randomized trials involving liver resection, TachoSil was compared to traditional methods like argon beam coagulation and stitches.

Numerical data from these trials showed that TachoSil achieved hemostasis in approximately 75% to 80% of patients within the first 3 minutes, significantly faster than the 40% to 50% success rate seen with standard methods. Furthermore, research in cardiovascular surgery demonstrated that patients treated with TachoSil had a lower incidence of post-operative “re-bleeding” and required fewer blood transfusions. This increased efficacy not only saves lives but also reduces the total time a patient spends under anesthesia.

Safety Profile and Side Effects

Black Box Warning

There is currently no Black Box Warning for TachoSil. However, it is strictly contraindicated for intravascular use (it must never be injected into a blood vessel).

Common side effects (>10%)

Because TachoSil is used during major surgery, it can be difficult to distinguish side effects of the drug from the surgery itself. Common reactions include:

• Mild to moderate fever (post-operative pyrexia).
• Localized redness or itching at the surgical site.
• Standard post-surgical pain and inflammation.

Serious adverse events

• Thrombosis Risk: If the proteins from the sponge accidentally enter a large blood vessel, they could cause a blood clot (thromboembolism) elsewhere in the body.
• Hypersensitivity: Rare but severe allergic reactions or anaphylaxis can occur, particularly in patients with an allergy to horse (equine) proteins, as the collagen is derived from horses.
• Adhesion Formation: The sponge may cause tissues to stick together inappropriately as they heal (intestinal obstructions or abdominal adhesions).

Management Strategies

Surgeons manage these risks by ensuring the patch is trimmed to the correct size so it does not overlap onto unwanted areas. If a patient shows signs of a severe allergic reaction (such as low blood pressure or difficulty breathing), the medical team provides immediate emergency support with antihistamines or epinephrine.

Research Areas

Current research into TachoSil and related BIOLOGIC sealants is focusing on the development of “smart” sponges. Active clinical trials are investigating sponges that are pre-loaded with antibiotics to prevent infections at the same time they stop bleeding. Additionally, researchers are exploring novel delivery systems for robotic and laparoscopic surgery, where the patch must be folded and inserted through a tiny tube before being unfolded and applied to the tissue.

Disclaimer: The research mentioned regarding the development of “smart” sponges pre-loaded with antibiotics and novel delivery systems for robotic or laparoscopic surgery is an active area of investigation in 2026. While these innovations aim to enhance surgical outcomes and infection control, their clinical use is distinct from the current FDA-approved application of TachoSil as a topical adjunct to hemostasis in cardiovascular and hepatic surgery.

Patient Management and Practical Recommendations

Pre-treatment Tests

Since TachoSil is used during surgery, standard pre-operative tests are required to assess the patient’s baseline clotting status:

• Complete Blood Count (CBC): To check platelet levels.
• Coagulation Profile (PT/INR and aPTT): To see how fast the blood currently clots.
• Liver and Kidney Function Tests: To ensure the body can process surgical medications.

Precautions during treatment

• Vigilance for Thromboembolism: After surgery, the care team monitors for signs of blood clots, such as sudden leg swelling or shortness of breath.
• Infection Monitoring: Because TachoSil is a foreign material left inside the body, doctors remain vigilant for signs of abscess or infection near the application site.
• Transfusion Triggers: While TachoSil stops bleeding, the hematologist will continue to monitor the patient’s hemoglobin levels to determine if a transfusion is still necessary.

“Do’s and Don’ts” List

• DO inform your surgeon if you have a known allergy to horse-derived products or human blood products.
• DO ask your care team about the specific hemostatic agents used if you have religious or personal concerns about human-derived proteins.
• DON’T worry about the sponge being removed; TachoSil is biodegradable and will be naturally absorbed by your body over 4 to 6 weeks.
• DON’T stop your regular blood-thinning medications (like aspirin or warfarin) before surgery unless explicitly instructed by your surgeon or hematologist.

Legal Disclaimer

For informational purposes only, does not replace professional medical advice from a qualified healthcare provider. The use of hemostatic agents like TachoSil is at the discretion of the surgical team based on the specific clinical situation. Always consult with your physician to understand the risks and benefits of any surgical procedure and the materials used during your care.